Werewolf Therapeutics Inc. - HOWL Net earnings per share for the last four quarters

Official company branding of Werewolf (HOWL)

The market dynamics of Werewolf Therapeutics (HOWL) demonstrate an EPS of 55.60. Werewolf Therapeutics is implementing the PREDATOR system for the local release of cytokines within tumors, backed by a robust scientific foundation. Financial stability during the development of new drugs is secured through significant payments from global pharma behemoths. Management aims to create a safe therapy with minimal complications while attracting new major allies.

Werewolf Therapeutics, Inc. (HOWL) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/14/2026

HOWL (Werewolf Therapeutics Inc.): analytical breakdowns and indicator data

- current price and projected stock value:
Price Performance Chart werewolftx.com|HOWL - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization Werewolf Therapeutics, Inc.|HOWL - Total Company Value
- book value of equity indicators:
Accounting Value per Share Werewolf Therapeutics|HOWL - Company Book Value|Market Cap to Net Assets Ratio werewolftx.com|HOWL - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Werewolf Therapeutics|HOWL - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Werewolf Therapeutics, Inc.|HOWL - Company Debts|Debts to Book Value Werewolf Therapeutics|HOWL - Company Long-Term Liabilities|Short-Term Indebtedness Werewolf Therapeutics|Intermediate Liquidity Ratio werewolftx.com
- earnings and market multiples details:
HOWL - Net Profit|Expected Net Income Werewolf Therapeutics|HOWL - P/E Multiple|Projected Price to Earnings Ratio Werewolf Therapeutics, Inc.|HOWL - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Werewolf|HOWL - Operating profit EBITDA|Net earnings per share (EPS TTM) Werewolf Therapeutics|HOWL - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months werewolftx.com|HOWL - Net earnings per share growth this year|Expected net earnings per share growth next year Werewolf Therapeutics
- revenue and sales details:
HOWL - Company Sales|Company Future Sales Volume werewolftx.com|HOWL - P/S Multiple|Market Cap to Future Revenue Ratio Werewolf Therapeutics, Inc.
Initial company analysis:HOWL, Werewolf Therapeutics
Mass-produced product of Werewolf Therapeutics, Inc.

Werewolf Therapeutics (HOWL) monetizes its proprietary PREDATOR technology, which minimizes the toxicity of immuno-oncology drugs to accelerate clinical trials. This trend is reflected through the calculation of the annual growth in earnings per share over the last 12 months, allowing investors to assess the real efficiency of innovation capitalization by analyzing the annual change in net income per share over a rolling period.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months